Profusa, Inc. (PFSA)

NCM – Цена в реальном времени. Валюта: USD

0.11

-0.00 (-3.05%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

0.11

-0.00 (-1.92%)

После закрытия: Jun 26, 2026, 7:45 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Profusa, Inc. (PFSA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Profusa, Inc. (PFSA)

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Profusa Receives Favorable Nasdaq Listing Determination

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

Видео

No Data

Пресс-релизы

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Profusa Receives Favorable Nasdaq Listing Determination

Search stocks

Profusa, Inc. (PFSA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Profusa, Inc. (PFSA)

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Profusa Receives Favorable Nasdaq Listing Determination

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform

Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

Видео

No Data

Пресс-релизы

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Profusa Receives Favorable Nasdaq Listing Determination